Candel Therapeutics, Inc. on December 15, 2023, Jason A. Amello resigned from his position as the principal financial officer and principal accounting officer of the Company, effective January 12, 2024, to pursue another opportunity. On January 12, 2024, the board of directors of the Company unanimously appointed Charles Schoch as the Company?s interim principal financial officer and principal accounting officer, effective January 12, 2024. Mr. Schoch, age 39, has served as the Company?s Vice President of Finance and Corporate Controller since March 2023.

Mr. Schoch joined the Company in November 2021 and has served in various financial reporting and accounting positions of increasing responsibility. Prior to joining the Company, Mr. Schoch was the Corporate Controller at Corbus Pharmaceuticals from September 2020 to November 2021 and previously worked in the Health Industry assurance practice of PricewaterhouseCoopers from September 2013 to August 2020. Mr. Schoch holds an M.B.A. and M.S.A. from Northeastern University and a B.S. in Business Administration with a concentration in Finance from Elon University.

Mr. Schoch is a Certified Public Accountant in the Commonwealth of Massachusetts.